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was 38.2 years (SD = 12.6) and 62.7% were female. 85.9% of our respondents were 
born outside Canada and 71.8% were ethnically from Asian areas. Effectiveness of 
the preventive treatment (Risk of developing active TB after treatment, −0.23, p < 
0.001), Risk of developing liver damage (−0.16, p < 0.001), Length of treatment 
(−0.05, p < 0.001), Risk of developing skin rash (−0.03, p = 0.002), and Risk of 
developing fatigue (−0.03, p = 0.009) were signiﬁcant determinants of respondents’ 
choices of preventive treatment. The negative preference estimates revealed that 
respondents were averse to higher risk of developing active TB, higher risk of develop-
ing liver damage, skin rash and fatigue, and longer period of treatment. Frequency of 
clinic visit was not a signiﬁcant factor. Respondents’ preferences varied according to 
their socio-demographic characteristics, past experiences of TB, BCG vaccination 
status, and the reason for tuberculin skin test. CONCLUSIONS: The results suggest 
that respondents were consistently in favor of LTBI preventive treatment with higher 
effectiveness, less side effects and shorter length.
PRS35
COMPARISON OF PATIENT REPORTED OUTCOMES BASED ON THE 
MINNESOTA NICOTINE WITHDRAWAL SCALE (MNWS) USING 
ABSTINENCE PROFILES IN TREATMENTS WITH VARENICLINE AND 
TRANSDERMAL NICOTINE PATCH (NRT)
Marton JP1, Zou KH1, Russ C1, Willke RJ2
1Pﬁzer, Inc, New York, NY, USA, 2Pﬁzer, Inc, Peapack, NJ, USA
OBJECTIVES: To conduct a post-hoc analysis of the time-courses of MNWS item or 
domain scores (MNWS scores) and weekly point prevalence of abstinence (PVR) 
during the treatment phase of a previously-published (Aubin et al, 2008) randomized 
open-label clinical trial of varenicline (N = 376) vs. NRT (N = 370). METHODS: 
Current cigarette smokers, motivated to quit smoking, participated in the trial and 
completed the MNWS instrument. Descriptive statistics (mean ± standard error) of 
the MNWS scores from weeks 2 to 7 were computed. Time-course comparisons strati-
ﬁed by PVR were performed, with weekly responders deﬁned by PVR = 0 and non-
responders otherwise. Multivariate repeated-measures mixed-effects regression was 
conducted for each MNWS domain score as the outcome variable. Covariates included 
baseline, treatment, patient characteristics, smoking history and PVR. Statistical sig-
niﬁcance was reached when two-sided p ≤ 0.05. RESULTS: The mean baseline MNWS 
scores of varenicline vs. NRT were comparable. By PVR, varenicline signiﬁcantly 
reduced the mean urge to smoke vs. NRT in weeks 2, 3, 4 and 5 (0.45 ± 0.10; 0.28 
± 0.09; 0.27 ± 0.10; 0.27 ± 0.09, respectively; all p < 0.01) among responders, and 
in weeks 2 to 6 (0.59 ± 0.13; 0.44 ± 0.14; 0.46 ± 0.16; 0.52 ± 0.18; 0.38 ± 0.17; all 
p < 0.03) among non-responders. The mean negative affect scores were signiﬁcantly 
lower in weeks 2 to 5 and 7 (0.31 ± 0.07; 0.20 ± 0.06; 0.18 ± 0.07; 0.23 ± 0.07; 0.13 
± 0.06; all p < 0.03) among responders and in week 2 (0.22 ± 0.11; p < 0.04) among 
non-responders. Additionally, restlessness was signiﬁcantly reduced in weeks 2 to 5 
(0.45 ± 0.10; 0.33 ± 0.09; 0.22 ± 0.09; 0.22 ± 0.08; all p < 0.02) among responders 
and in week 2 (0.42 ± 0.14; p < 0.003) among non-responders, and similarly the 
reduction of increased appetite (0.38 ± 0.18; p < 0.05) among nonresponders in week 
7. CONCLUSIONS: Overall, lower mean patient-reported MNWS scores associated 
with symptoms of tobacco withdrawal were observed for varenicline than for NRT, 
reaching statistical signiﬁcance, particularly among abstainers. Differences in the 
dynamics of treatment effects along with concomitant abstinence status warrant 
further bivariate analyses.
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OBJECTIVES: It is expected that chronic diseases will account for 73% of deaths and 
60% of the global diseases by 2020. India is experiencing a fast health transition, in 
2005 chronic disease contributed to an estimated 53% of deaths and 44% of disabil-
ity-adjusted life years lost. Chronic diseases are a serious public health issue, particu-
larly because they require long-term therapy. Asthma, a major chronic disease, has 
become a cause of global concern in terms of its increasing prevalence, morbidity, and 
economic impact. Improving access to essential medicines and adherence to standard 
treatment guidelines can decrease the morbidity and mortality. The present scenario 
of access to essential medicines and treatment behaviour to asthma in India is inves-
tigated. METHODS: Recent studies conducted (2007–2009) on asthma management 
and adherence to therapy were analysed. Data on availability and price of two essential 
medicines for asthma, beclomethasone and salbutamol inhalers was collated from ﬁve 
medicine price studies conducted (2003–04) in ﬁve states of India, Haryana, Karna-
taka, Maharashtra, Rajasthan and Chennai (capital, Tamil Nadu state). RESULTS: 
Except for Rajasthan no inhalers were on state essential medicine list and were not 
available in any of the public facility; in Rajasthan these inhalers were available only 
in public facility of capital city. Results of the asthma management studies indicate 
poor knowledge regarding treatment of bronchial asthma by prescribers, pharmacists 
and by patients and asthma is not treated according to standard treatment guidelines. 
More than 80% patients and/or prescribers are treating acute episodes, rather than 
focusing on long-term asthma control. Ninety-two percent of patients alter the dose 
of inhaled corticosteroids after the acute attack. CONCLUSIONS: Since the incidence 
of chronic diseases are increasing rapidly in India, there is urgent need for improving 
access to essential medicines, treatment guidelines, policy making, patient & provider 
education, and resource allocation for chronic diseases, like bronchial asthma.
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OBJECTIVES: This study examined the asthma medications prescribing patterns 
among pediatric asthma visits in ambulatory care settings in the United States. 
METHODS: A retrospective cross-sectional analysis of National Ambulatory Medical 
Care Survey (NAMCS) and the outpatient data of the National Hospital Ambulatory 
Medical Care Survey (NHAMCS) of year 2006–2007 was conducted involving chil-
dren aged less than 18 years and diagnosed with asthma (ICD-9-CM 493.XX). The 
analyses focused on medications based on the guidelines of the National Asthma 
Education and Prevention Program (NAEPP). Descriptive statistics was used to 
examine the prescribing pattern. RESULTS: According to NAMCS and NHAMCS, 
there were18 million (0.87%) physician ofﬁce visits by children with asthma. Long 
Acting β2 Agonist was highly prescribed among (57.50%) ofﬁce visits, followed by 
Leukotrine Modiﬁers (29.91%) and Inhaled Corticosteroids (27.88%). Oral Cortico-
steroids and Short Acting β2 Agonist were prescribed in 15.99%, and 14.18% of 
ofﬁce visits, respectively. In terms of individual medicines, Albuterol, was mostly 
prescribed among 10.43 million visits, followed by Montelukast, 5.42 million visits. 
Prednisolone was prescribed in 2.71 million visits and Levalbuterol was prescribed in 
2.36 million visits. CONCLUSIONS: Long Acting β2 Agonist and Leukotrine Modi-
ﬁers was the most highly prescribed medication class and Albuterol and Montelukast 
were highly prescribed individual medications in pediatrics asthma ambulatory care 
visits in the United States.
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OBJECTIVES: To examine the prescribing pattern of drugs for the treatment of 
Chronic Obstructive Pulmonary Disease (COPD) in ambulatory care visits and to 
assess the variation in the prescription of ﬁrst line of therapy across sex, race and 
geographic region. METHODS: Data of 2006–2007 National Ambulatory Medical 
Care Survey (NAMCS) and outpatient ﬁles of National Hospital Ambulatory Medical 
Care Survey (NHAMCS) were analyzed. Sample data was weighted to provide US 
national estimates. Adults more than 25 years of age were included in the study and 
COPD visits were identiﬁed (ICD-9-CM: 491,492,496). First line of therapy was 
deﬁned as prescription of either beta-agonist or anticholinergics. Descriptive weighted 
analysis was performed to examine the prescribing pattern of drugs and multivariate 
logistic regression using complex survey design was conducted to identify variation 
for ﬁrst line of therapy across sex, race and region, while controlling for age, tobacco 
use, insurance, metropolitan area, and region. RESULTS: In 2006–2007, COPD 
accounted for 70.25 million (95% CI: 60.69–79.81) ambulatory care visits by adult 
patients, representing 3.3% of the total ambulatory visits. Of these visits, majority 
were made by females (59.14%), whites (87.31%) and living in the southern region 
(44.78%). COPD medications were only prescribed in 42.13% of the visits. Highly 
prescribed medications were bronchodilators (34.33%), followed by combination 
therapy (9.66%) and inhaled corticosteroids (2.71%). First line of therapy was pre-
scribed at 25.17% (95% CI: 21.62–28.72) visits: 19.16% visits received beta-agonist 
and 11.84% visits received anticholinergics. No variation was found across sex, 
race, and region for the prescription of ﬁrst line of therapy for COPD. CONCLU-
SIONS: Bronchodilators were highly prescribed medication for COPD in outpatient 
visits. The ﬁrst line of therapy did not vary signiﬁcantly across sex, race and region 
for COPD.
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OBJECTIVES: To ﬁnd out demographic factors predicting inhaled corticosteroid 
utilization among asthma patients. METHODS: The study utilized data from the 
four-state sample of National Asthma Survey (NAS), sponsored by the National 
Center for Environmental Health (NCEH), Centers for Disease Control. The study 
population consisted of patients with persistent asthma as (deﬁned by the symptoms 
score based on NHLBI guidelines). Frequency distributions were made to characterize 
the study population. Logistic regression was carried out to determine the odds of 
reporting use of inhaled corticosteroids across various demographic variables (Age, 
gender, race, income level, insurance coverage, and disease severity). Data was ana-
lyzed using SAS v9.0. RESULTS: Underutilization of inhaled corticosteroids (ICSs) 
was found to exist in the asthmatic patients as over half of our study population 
(52.6%,n = 323)did not even report the use of ICSs. Disparities were also found to 
exist in our study across various variables. Blacks were found to have much lower 
odds of using ICSs when compared to other races (OR,0.572;CI,0.566–0.579). Black 
uninsured children also demonstrated similar trends. Patients having some form of 
